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Abstract
Background: Hitherto, risk prediction models for preoperative ultrasound-based diagnosis of ovarian tumors were
dichotomous (benign versus malignant). We develop and validate polytomous models (models that predict more
than two events) to diagnose ovarian tumors as benign, borderline, primary invasive or metastatic invasive. The
main focus is on how different types of models perform and compare.
Methods: A multi-center dataset containing 1066 women was used for model development and internal
validation, whilst another multi-center dataset of 1938 women was used for temporal and external validation.
Models were based on standard logistic regression and on penalized kernel-based algorithms (least squares
support vector machines and kernel logistic regression). We used true polytomous models as well as combinations
of dichotomous models based on the ‘pairwise coupling’ technique to produce polytomous risk estimates. Careful
variable selection was performed, based largely on cross-validated c-index estimates. Model performance was
assessed with the dichotomous c-index (i.e. the area under the ROC curve) and a polytomous extension, and with
calibration graphs.
Results: For all models, between 9 and 11 predictors were selected. Internal validation was successful with
polytomous c-indexes between 0.64 and 0.69. For the best model dichotomous c-indexes were between 0.73
(primary invasive vs metastatic) and 0.96 (borderline vs metastatic). On temporal and external validation, overall
discrimination performance was good with polytomous c-indexes between 0.57 and 0.64. However, discrimination
between primary and metastatic invasive tumors decreased to near random levels. Standard logistic regression
performed well in comparison with advanced algorithms, and combining dichotomous models performed well in
comparison with true polytomous models. The best model was a combination of dichotomous logistic regression
models. This model is available online.
Conclusions: We have developed models that successfully discriminate between benign, borderline, and invasive
ovarian tumors. Methodologically, the combination of dichotomous models was an interesting approach to tackle
the polytomous problem. Standard logistic regression models were not outperformed by regularized kernel-based
alternatives, a finding to which the careful variable selection procedure will have contributed. The random
discrimination between primary and metastatic invasive tumors on temporal/external validation demonstrated
once more the necessity of validation studies.
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Medical diagnostic studies typically involve predicting
the presence or absence of a target condition. The
development of prediction models then becomes a pro-
blem of binary classification, even though often multiple
differential diagnoses exist. There are statistical and
other mathematical techniques to simultaneously predict
three or more conditions, but these are underused [1].
Possible reasons for this may be increased complexity,
lack of knowledge or lack of data, or the force of habit.
If we take as an example the characterization of ovarian
tumors, diagnostic models have consistently focused on
predicting malignancy versus benignity [2-5]. Notwith-
standing the importance of the differentiation between
cancerous and non-cancerous tumors, this dichotomiza-
tion ignores the relevant heterogeneity in malignant
tumors. It is known that different types of malignant
tumors may be managed differently [6-9], thereby
improving the prognosis and reducing unnecessary
financial cost or hospitalization. Therefore, in this work,
we focus on polytomous risk prediction models to char-
acterize ovarian masses as benign, borderline malignant,
primary invasive, or metastatic invasive.
Ovarian cancer is a common and lethal cancer. The
American Cancer Society reports that ovarian cancer has
the fifth highest death rate of all cancers among females
in the United States, with about 15,000 deaths per year
[10]. When confronted with an ovarian mass, an accurate
preoperative diagnosis is important to decide on the opti-
mal treatment. For benign tumors management may
involve a simple “watch and wait” strategy or minimal
access surgery. Misdiagnosis of a benign mass as malig-
nant may lead to a woman undergoing a radical surgical
procedure for no reason. Hence the consequences of a
misclassification may be very serious.
Primary invasive malignancies originate in the ovary,
whilst metastatic invasive malignancies originate else-
where (e.g. breast, colon, stomach, pancreas) but have
spread to the adnexal structures. Borderline tumors are
of ‘low malignant potential’, representing less aggressive
tumors that are less life-threatening. From a clinical
viewpoint differentiating between these different types of
tumor has significant relevance. Primary invasive tumors
are typically managed using invasive techniques such as
laparotomy for staging, interval-debulking surgery or
cytoreduction [11]. An intervention for a borderline
tumor may be relatively conservative in young women
where preservation of fertility is a major issue [9]. For
metastatic disease the management option may be influ-
enced by the primary site of malignancy. The differen-
tiation between borderline and invasive tumors is one of
the most pertinent clinical issues beyond the differentia-
tion between benignity and malignancy.
In the medical literature, risk prediction models are
often based on a logistic regression analysis. In this study,
we applied several alternatives to the standard multinomial
logistic regression model (MLR) for two reasons. Firstly, in
the MLR model the selected variables are used to distin-
guish between all events whereas variables may be impor-
tant only for a subset of them [12]. Therefore, we also
performed polytomous classification by combining dichot-
omous logistic regression models to investigate whether
this resulted in better performance. Secondly, algorithms
more flexible than logistic regression are available, many
of them having their origin in the machine learning area.
We applied kernel-based polytomous methods based on
least squares support vector machines [13] and kernel
logistic regression [14]. Another important advantage of
these models is that they include a regularization (or pena-
lization) parameter in their standard model formulation to
avoid overfitting, a procedure comparable to shrinkage
methods for logistic regression models [15]. Because bor-
derline and metastatic tumors had low prevalence such
that there was a risk of overfitting, we aimed to compare
the performance of these approaches with those based on
standard logistic regression analysis (without shrinkage).
All algorithms implemented in this study result in prob-
abilities for each of the four events considered.
As explained in the next section, the prediction mod-
els were developed and tested (i.e. internally validated)
on data from a large international multi-center study.
Thorough validation of any developed prediction model
is essential to assess the model’s robustness and general-
izability [16]. Therefore, a temporal and external valida-
tion was performed on a large dataset that was collected
after model development.
Methods
Design and setting
This is an international multi-center cross-sectional
study, involving women presenting with an adnexal
mass to experienced ultrasound examiners in oncologi-
cal referral centers, referral centers for ultrasonography,
or regional hospitals.
Data
The International Ovarian Tumor Analysis (IOTA) group
[17] collected data from 1066 non-pregnant women with
at least one persistent adnexal mass (including para-
ovarian and tubal masses). All patients underwent an
ultrasound examination by the principal investigator, a
gynecologist or radiologist specialized in gynecological
ultrasound. Nine clinical centers participated from Italy
(4), France (2), Belgium (1),S w e d e n( 1 ) ,a n dt h eU n i t e d
Kingdom (1). Only patients who were operated on within
120 days after the ultrasound examination were included.
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clinicians based on the clinical picture and local manage-
ment protocols. More information on inclusion and exclu-
sion criteria is presented in [18]. Data collection was
standardized to enhance reproducibility of the measure-
ments [17]. The primary aim of the IOTA study was the
development of dichotomous prediction models contrast-
ing benign with malignant tumors [5,18,19].
Data included personal and family history of ovarian
and breast cancer, demographic data, grey scale and
color Doppler results from ultrasound examination (i.e.
more than 40 morphologic and blood flow characteris-
tics describing the tumor), and the presence or absence
of pain during examination. After checking for high
inter-variable dependencies, 36 variables remained. The
outcome of interest was the histological diagnosis of the
mass as benign, borderline, primary invasive, or meta-
static. Eight hundred tumors were benign (75%), 55
were borderline (5%), 169 were primary invasive (16%),
and 42 were metastatic (4%). The dataset was split up in
a training set containing 754 patients (71%) for model
development, and a test set containing the remaining
312 patients for the internal validation of the models.
The split was stratified for center and outcome. We did
not use bootstrapping for the internal validation because
we did not use fully automated variable selection.
Because the number of borderline and metastatic
tumors was limited, we selected 16 variables that were
thought to be of potential relevance based on the litera-
ture and on subject matter knowledge from clinical
experts. This improved the situation, yet the number of
borderline and metastatic invasive tumors relative to the
number of candidate variables remained small.
After model development, the IOTA group collected a
new set of data from 19 centers [20]. Seven centers also
contributed to the initial dataset, such that the 941
patients contributed by these centers were used for a tem-
poral validation of the models’ performance (654 benign,
69 borderline, 186 primary invasive, 32 metastatic). The 12
centers that did not contribute to the initial dataset were
located in Italy (6), Belgium (1), Sweden (1), Poland (1),
Czech Republic (1), China (1) and Canada (1). The 997
patients contributed by these 12 centers were used for the
external validation of the models (742 benign, 42 border-
line, 187 primary invasive, 26 metastatic).
The research protocols for the collection of the devel-
opment and validation datasets were ratified by the local
ethics committee at each recruitment center.
The kernel-based algorithms
Least squares support vector machines
Standard support vector machine (SVM) classifiers [21]
are non-probabilistic dichotomous models. First, the
predictor space (i.e. the multidimensional scatter plot of
the predictors) is mapped into a high dimensional ‘fea-
ture space’.T h ea i mi st of i n daf e a t u r es p a c ew h e r ea n
acceptable linear model can be developed in order to
deal with possible nonlinearities in the original predictor
space. The linear separation between the events in the
feature space tries to maximize the margin between the
two groups - hereby imposing regularization - while at
the same time controlling the number of misclassifica-
tions. A good balance between both is desired: too
much focus on margin maximization leads to an overly
simplistic model, too much focus on misclassification
minimization leads to an overfitted model. A regulariza-
tion (penalization) parameter is included to control the
trade-off. Through the use of a positive definite kernel
function it is not necessary to directly work in the high
dimensional feature space. The choice of kernel affects
how the linear separation in the feature space relates to
the predictor space. The linear kernel x
Tz (with x and z
two vectors of predictor values representing two
patients) results in linear classifiers in the predictor
space whereas other kernels such as the popular Gaus-
sian kernel, exp −− ( ) xz
2
2 2  with the kernel para-
meter s that has to be tuned, result in nonlinear
classifiers. Least squares SVMs (LS-SVMs) are a variant
of SVMs that work much faster due to small changes in
the cost function [13]. However, performance of LS-
SVMs is similar to that of SVMs [22].
We overcame the non-probabilistic nature of standard
(LS-)SVMs through the use of a Bayesian framework
[23]. Using the distribution of the outcome in the devel-
opment data as prior event probabilities, dichotomous
event probabilities were obtained based on the LS-SVM
output. Hyperparameters such as the regularization and
kernel parameters are automatically tuned by the Baye-
sian procedure.
Kernel logistic regression (KLR)
In essence, KLR only differs from SVMs with respect
to the adopted loss function. However, KLR directly
results in probabilistic output and is easily extended to
a multinomial version (MKLR). We used an MKLR
algorithm that is based on LS-SVMs [14]. The basis of
the algorithm is a regularized MLR model that is
solved using a penalized negative log likelihood func-
tion using iteratively regularized re-weighted least
squares. By mapping the predictor space into a high
dimensional feature space using a positive definite ker-
nel and applying in each iteration a model with the
s t r u c t u r eo fa nL S - S V M ,ak e r n e lv e r s i o no fM L Ri s
obtained. The hyperparameters were tuned using five-
fold cross-validation (CV).
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dichotomous models
MLR and MKLR simultaneously distinguish between all
events. Such ‘true’ polytomous models are also called
all-at-once methods. Other methods combine dichoto-
mous models, and vary with respect to the type of
dichotomous models and the method to combine them.
When polytomous problems are decomposed, the
dichotomous models often contrast each event with all
other events (1-versus-all approach) or with each other
event (1-versus-1 approach). We favored the 1-versus-1
method for the following reasons. Firstly, from a clinical
viewpoint it is interesting to see which variables are use-
ful to discriminate between each pair of events. Sec-
ondly, it is mathematically more efficient because
lumping together different events in the 1-versus-all
approach may result in a complex (i.e. heterogeneous)
‘meta-event’. Each dichotomous model was developed
on the training cases belonging to the two events
involved, and was applied to all test set or validation
cases. The probabilities from the 1-versus-1 models
were combined to obtain polytomous probabilities (i.e.
probabilities for each of the four events that sum to
one) using the efficient technique of pairwise coupling
[24]. The polytomous probabilities πi are estimated by
solving the following linear system:

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Variable selection
For logistic regression models, we were careful regarding
variable selection due to the small number of borderline
and metastatic tumors. We did not use automated pro-
cedures based on p-values to directly select a final set of
predictors because we prefer variable selection based on
criteria similar to the model evaluation criteria, and
because automated selection is highly unstable and
bound to overfit when there are small groups and a
large number of candidate variables [25]. The procedure
was as follows. Using stepwise, backward, and manual
selection procedures, several possible variable sets were
generated. The final set of predictors was selected using
three criteria. Two criteria measure information content:
t h eA k a i k ea n dt h eB a y e s i a nI n f o r m a t i o nC r i t e r i o n
(AIC, BIC) [26]. These criteria penalize a model’sl o g
likelihood for the number of predictors. AIC has the
tendency to be liberal whereas BIC tends to be conser-
vative. Therefore, we prefer models with fairly low
values for both criteria. The third and most important
criterion was the discrimination performance assessed
by the average dichotomous c-index for each event after
20 independent runs of stratified five-fold CV. The
dichotomous c-index equals the area under the ROC
curve.
For the kernel-based methods, a forward selection
algorithm based on rank-one updates of the kernel
matrix in the context of standard LS-SVMs was used
[27]. It is computationally intensive to select variables
by repeatedly adding the variable that gives the best per-
formance gain based on leave-one-out cross-validation
(LOO-CV). When using LS-SVMs, this strategy can be
speeded up significantly for two technical reasons.
Firstly, the LS-SVM model structure allows for the fast
computation of model performance measures based on
LOO-CV. Secondly, the LS-SVM model can be updated
using rank-one updates in the kernel matrix such that
adding a variable does not require the re-computation
of the model. This new method, abbreviated as R1U, is
very fast, but is currently only available for linear-kernel
LS-SVMs. Using the training set, we observed that a lin-
ear kernel LS-SVM with R1U-selected variables per-
formed clearly better than linear or nonlinear LS-SVMs
using variables that were selected using an advanced
nonlinear procedure [28]. In each step, we used the c-
index estimated by LOO-CV to determine which vari-
able to add. We re-tuned the regularization parameter
in each step using a grid search to find the value with
maximal c-index.
Overview of methods used to diagnose ovarian tumors
The methods that were used in this study can be
divided into two groups based on the variable selection
method. The first group consists of two logistic regres-
sion-based methods using logistic regression-based vari-
able selection: MLR, and pairwise coupling of 1-versus-1
logistic regression models (LR-PC). The second group
consists of three kernel-based methods using variables
from R1U selection: MKLR, and pairwise coupling of 1-
versus-1 Bayesian LS-SVMs (LSSVM-PC) or KLR mod-
els (KLR-PC). We add one logistic regression-based
method to the second group for means of comparison:
pairwise coupling of 1-versus-1 logistic regression mod-
els (LR-PC2).
Evaluation of model performance
Model training was based on training data only. The
models were then applied to the validation datasets for
evaluation and comparison. Model evaluation was based
primarily on a polytomous extension of the c-index.
Then the standard c-index (i.e. the area under the ROC
curve) was used to assess discrimination between every
pair of events. The polytomous extension is a measure
that bears similarity with the volume under the surface
index for trichotomous classification [29]. Assume a set
of cases consisting of one case from each event. We
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was obtained if, for all events, the predicted probability
for an event was largest for the case with this particular
event [30]. More generally, we counted the number of
events for which this was true. For a 4-event problem,
with N1 to N4 number of cases per event, this polyto-
mous c-index was then written as
1
4 1234
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with C(n1, n 2, n 3, n 4) the number of events for
w h i c hi th e l dt h a tt h ee v e n t ’s predicted probability was
largest for the case with that event. Thus C ranged
between 0 and 4. The average C over all sets was
divided by 4 to obtain a value between 0 and 1 (with
0.25 for random discrimination). This polytomous index
can be interpreted as the probability to correctly identify
a case from a randomly chosen event within a set of 4
cases.
Calibration was assessed using calibration graphs that
related predicted probabilities to actual probabilities
using loess smoothing [31,32]. This resulted in four
graphs, one per event.
Results
Variable selection results
The variables selected for the MLR model and for each
dichotomous LR problem are presented in Table 1.
Nine variables were selected for MLR. For LR-PC, how-
ever, the situation was more complicated. In order to
keep the total number of selected variables for the six
dichotomous models under control, selection for these
models was intertwined. We finally selected three to five
variables for each dichotomous problem such that LR-
PC used ten variables in total. A similar issue held for
the R1U selection. Here, for each dichotomy the vari-
ables were ranked based on the LOO c-index. Then,
starting from these rankings, 20 runs of five-fold CV on
the c-index were used to select a final variable set per
dichotomy while controlling the total number of
selected variables. This extensive variable selection strat-
egy resulted in the selection of three to five variables
per dichotomous problem, summing up to 11 variables
in total for LSSVM-PC, KLR-PC, and LR-PC2 (Table 1).
For MKLR, all these 11 variables were used. Thus, the
number of selected variables varies between nine and
eleven, which is similar to the number of selected vari-
ables for the benign-versus-malignant models [5,18,19].
Descriptive statistics for the selected variables are pre-
sented in Table 2.
Internal validation (test set results)
On the test set, the polytomous c-index varied between
0.64 for the two true polytomous models (MLR and
MKLR) and 0.69 for LR-PC2 (Table 3). Thus, for a ran-
domly chosen event, there is a 69% chance that the
probability from LR-PC2 for this event is highest for a
case with this event than for a case with any of the
other three events. Table 4 presents pairwise c-indexes
for the best models. These results show that pairwise
discrimination was generally very good, with the lowest
c-index for the discrimination between primary invasive
and metastatic invasive tumors (c 0.73). There were very
few borderline and metastatic tumors in the test set,
which hampered reliable conclusions. Calibration was
g o o d ,e x c e p tt h a tt h er i s ko fab o r d e r l i n et u m o rw a s
overestimated (cf. infra).
Temporal and external validation
When aiming to implement a model into clinical prac-
tice, good temporal and external validation results are
essential. The results that we obtained are presented in
Table 3, and show a performance decrease relative to
the internal validation. On temporal validation the poly-
tomous c-index varied between 0.57 for MKLR and 0.60
for LR-PC, on external validation between 0.58 for MLR
and MKLR and 0.64 for LR-PC2. Similar to the internal
validation, LR-PC2 and LR-PC were the best models.
The pairwise c-indexes for these models (Table 4) show
that pairwise discrimination among the three malignant
events clearly dropped on temporal and external valida-
tion. Most striking is the observation that discrimination
between primary invasive and metastatic invasive
tumors, which was acceptable on internal validation
(c 0.73), was random on temporal (c 0.51) and external
(c 0.56) validation. Discrimination between these two
tumor types and borderline tumors was still good with
c-indexes above 0.8. Benign tumors can be very well
separated from any malignant tumor type, even from
borderline tumors (c-indexes 0.9 or higher).
The temporal and external validation showed that
pairwise coupling of dichotomous models resulted in
models with superior discrimination compared to true
polytomous models. Also, logistic regression-based mod-
els produced better results than KLR or LS-SVM-based
models. Taken together, LR-PC2 produced the best
results. Calibration was clearly poorer on temporal and
external validation than on internal validation (cf. infra).
Further results for LR-PC2
Figure 1 shows box plots of LR-PC2’s predicted prob-
abilities for each event, once for the internal validation
data and once for the merged temporal and external
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probability of a specific event is on average higher for
tumors with that event compared to tumors with
another event. The box plots also show that borderline
tumors typically get a high probability for being benign,
and that it is less straightforward to separate primary
invasive tumors from metastatic invasive tumors. The
box plots for the temporal plus external validation data
show that the two types of invasive tumors were not
distinguishable at all, contrary to what the internal vali-
dation box plots suggested.
Calibration was better in probability ranges that con-
tained many patients (i.e. predicted probability of benign
tumor of 0.90 or more, probabilities of malignant events
up to 0.05-0.10) compared to other regions. The calibra-
tion curves are shown in Figure 2. On temporal and exter-
nal validation, LR-PC2 overestimates the probability of a
benign and a metastatic tumor, but underestimates the
probability of a borderline and a primary invasive tumor.
We addressed two important clinical issues. The first
issue is the role of tumor stage for the discrimination
between different tumor types [33]. Primary invasive
tumors can be well separated from benign and border-
line tumors, but it is of interest to look at primary inva-
sive stage I tumors and primary invasive stage II-IV
tumors separately. We focused on the aggregated tem-
poral and external validation data, and computed the
pairwise c-indexes for the two primary invasive sub-
groups when compared with benign, borderline, and
metastatic tumors. In the development data 32% of the
primary invasive tumors were stage I, 7% stage II, 50%
stage III, and 11% stage IV. In the temporal/external
validation data, primary invasive tumors were 25% stage
I, 9% stage II, 57% stage III, and 9% stage IV. Discrimi-
nation from benign tumors was very high for both pri-
mary invasive subgroups (c 0.92 for stage I, c 0.95 for
stage II-IV). Discrimination from borderline tumors was
clearly poorer for primary invasive stage I tumors
Table 1 Overview of selected variables
Dichotomous 1-versus-1 models
Variable MLR Ben vs Bord Ben vs
PrInv
Ben vs Meta Bord
vs
PrInv
Bord
vs
Meta
PrInv
vs
Meta
Logistic regression-based variable selection
Ascites × × × × × ×
Maximal diameter of solid part × × × × ×
Age × × ×
Entirely solid tumor × × × ×
Irregular internal cyst walls × × ×
Personal history of ovarian cancer × ×
Bilateral tumors × ×
Maximal diameter of lesion × ×
Papillary structures with blood flow × × ×
Unilocular tumor ×
R1U variable selection*
Ascites × × × × ×
Maximal diameter of solid part × × × ×
Age × × ×
Entirely solid tumor × × ×
Irregular internal cyst walls × × ×
Personal history of ovarian cancer × ×
Bilateral tumors ×
Maximal diameter of lesion ×
Papillary structures with blood flow ×
Number of papillations ×
Acoustic shadows ×
Ben: benign; PrInv: primary invasive; Bord: borderline; Meta: metastatic.
* R1U variable selection: variable selection within the framework of least squares support vector machines that is based on rank 1 updates of the kernel
matrix [27].
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tumors (c 0.85). Discrimination from metastatic tumors
was poor irrespective of stage (c 0.56 for stage I, c 0.53
for stage II-IV). The second important clinical issue is
ascites. The presence of ascites makes a diagnosis of pri-
mary invasive cancer highly likely. When the temporal
and external validation data were aggregated, 71% of the
patients with ascites had a primary invasive tumor, 13%
had a metastatic tumor, and 16% had a benign or bor-
derline tumor. However, it is important that prediction
models work well also in patients without ascites. In
this subgroup of patients, when combining the temporal
and external validation datasets, pairwise c-indexes were
0.91 for discriminating benign from borderline tumors,
0.93 for discriminating benign from primary invasive
tumors, 0.91 for discriminating benign from metastatic
tumors, 0.77 for discriminating borderline from primary
invasive tumors, 0.82 for discriminating borderline from
metastatic tumors, and 0.57 for discriminating primary
invasive from metastatic tumors. The polytomous c-
index was 0.59. This means that the LR-PC2 performed
well also in patients without ascites.
Finally, LR-PC2 can be directly compared with exist-
ing dichotomous models using the probability of a
Table 2 Descriptive statistics of selected variables for the training data set
Benign Border-line Primary invasive Meta-static
Variables N = 563 N =4 0 N = 121 N =3 0
Continuous
Age, years (median) 42 52.5 58 59
Maximum diameter of mass, mm (median) 63 108 98 73
Maximum diameter of solid part, mm (median) 0 22 51 54
Ordinal
Number of papillations (mean)# 0.35 1.70 1.43 0.93
Binary
Ascites (%) 3.2 12.5 50.4 40.0
Entirely solid tumor (%) 6.6 7.5 32.2 56.7
Irregular internal cyst walls (%) 33.6 67.5 88.4 83.3
Personal history of ovarian cancer (%) 0.9 5.0 0.8 10.0
Bilateral tumors (%) 17.6 12.5 41.3 33.3
Papillary structures with blood flow (%) 6.8 47.5 43.0 23.3
Acoustic shadows (%) 13.0 2.5 0.0 3.3
Unilocular tumor without solid component (%) 40.3 2.5 0.0 0.0
# Values are 0, 1, 2, 3, 4 (more than three).
Table 3 Validation results using a polytomous c-index
Internal validation (n = 312) Temporal validation (n = 941) External validation (n = 997)
Model
(# predictors)
Polytomous
c-index
(95% CI)
Difference with
best model
(95% CI)
Polytomous
c-index
(95% CI)
Difference with
best model
(95% CI)
Polytomous
c-index
(95% CI)
Difference with
best model (95% CI)
Group 1: logistic regression models
LR-PC (10) .67 (.58-.75) - .60 (.56-.65) - .60 (.55-.65) -
MLR (9) .64 (.56-.73) .025 (-.004; .053) .58 (.54-.62) .020 (.000; .040) .58 (.53-.62) .028 (.000; .058)
Group 2: kernel-based and logistic regression models (based on R1U variable selection)*
LR-PC2 (11) .69 (.60-.77) - .59 (.55-.64) - .64 (.59-.68) -
KLR-PC (11) .67 (.59-.75) .016 (-.013; .051) .58 (.54-.63) .012 (-.006; .027) .61 (.57-.66) .026 (.004; .049)
LSSVM-PC (11) .66 (.58-.75) .025 (-.007; .060) .58 (.54-.62) .015 (-.005; .035) .61 (.57-.65) .028 (.005; .052)
MKLR (11) .64 (.56-.73) .046 (.003; .086) .57 (.52-.62) .027 (.000; .056) .58 (.53-.62) .060 (.033; .092)
Models are ranked by the value of the polytomous c-index. Ben: benign; PrInv: primary invasive; Bord: borderline; Meta: metastatic; CI: confidence interval. 95%
CIs are computed using the bias-corrected bootstrap method using 1000 bootstrap samples.
* R1U variable selection: variable selection within the framework of least squares support vector machines that is based on rank 1 updates of the kernel
matrix [27].
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Page 7 of 12benign tumor to discriminate between benign and
malignant tumors. LR-PC2 obtained c-indexes of 0.939
and 0.954 on temporal and external validation, results
that are similar to the main dichotomous model from
the IOTA group with c-indexes of 0.945 and 0.956 on
the same datasets [20].
On http://homes.esat.kuleuven.be/~biomed/LRPC2/
lrpc2.htm we have made available an Excel sheet that
can be used to implement LR-PC2.
Comparison of LR-PC2 with a model based on automatic
stepwise variable selection
Variable selection for our models was partly based on
automatic procedures and partly on human interference.
We considered this appropriate, in particular for a
model such as LR-PC2 where six dichotomous models
with separate variable selection are combined. There-
fore, it was interesting to compare LR-PC and LR-PC2
with a similar model based on fully automatic variable
selection. We used standard forward stepwise selection
for each dichotomous model with p-value criteria for
variable entry and removal set at 0.05. The resulting
stepLR-PC model used 15 variables in total compared to
10 for LR-PC and 11 for LR-PC2. The polytomous c-
indexes of stepLR-PC were 0.64 on internal validation
(versus 0.67 and 0.69 for LR-PC and LR-PC2), 0.60 on
temporal validation (versus 0.60 and 0.59), and 0.58 on
external validation (versus 0.60 and 0.64).
Discussion
Methods for polytomous classification are underused in
medical applications. In this paper, we used various
methods for the probabilistic diagnosis of ovarian
tumors as benign, borderline, primary invasive, or meta-
static invasive. To the best of our knowledge, this is the
first time that prediction models for ovarian tumor diag-
nosis exceeded the basic differentiation between benign
and malignant tumors. Methods included true polyto-
mous (all-at-once) algorithms and algorithms that com-
bined dichotomous (1-versus-1) models using the
technique of pairwise coupling. The basic classification
algorithms were based on logistic regression, LS-SVMs,
and kernel logistic regression. All models were intern-
ally, temporally, and externally validated. Despite the
low number of borderline and metastatic tumors, inter-
esting and consistent results were obtained.
The results showed very good separation of benign,
borderline, and invasive tumors. This is an important
result because the ability to differentiate between bor-
derline and invasive tumors gives additional, highly use-
ful information for making sensible treatment decisions.
There is a clear difference in aggressiveness between
borderline and invasive tumors, and they are treated dif-
ferently. The use of a model such as LR-PC2 in clinical
practice would therefore be interesting. On http://
homes.esat.kuleuven.be/~biomed/LRPC2/lrpc2.htm we
have made available an Excel sheet that can be used to
implement LR-PC2. Unfortunately, the models were
unable to reliably discriminate between primary and
metastatic invasive tumors.
In the present study, the combination of 1-versus-1
models with pairwise coupling was an interesting alter-
native to true polytomous algorithms. The former
approach allowed for more fine-tuned variable selection,
and resulted in higher validation performance - as deter-
mined by the polytomous c-index - for both logistic
regression-based and kernel logistic regression-based
models. An advantage of 1-versus-1 models is their
increased flexibility by addressing subproblems that are
sometimes of particular interest to the clinician, for
example when the clinician hesitates between two diag-
noses only. The overall best model combined 1-versus-1
logistic regression models using pairwise coupling (LR-
PC2). For the discrimination between benign and
Table 4 Validation results using pairwise c-indexes
Model Ben vs Bord Ben vs PrInv Ben vs Meta Bord vs PrInv Bord vs Meta PrInv vs Meta
Group 1: logistic regression models
Internal: LR-PC .82 .95 .93 .88 .96 .73
Temporal: LR-PC .88 .95 .93 .81 .83 .51
External: LR-PC .88 .96 .93 .81 .89 .56
Group 2: kernel-based and logistic regression models (based on R1U variable selection)*
Internal: LR-PC2 .86 .94 .92 .88 .96 .73
Temporal: LR-PC2 .90 .94 .92 .81 .83 .51
External: LR-PC2 .91 .95 .93 .81 .89 .56
Models are ranked by the value of the polytomous c-index. Ben: benign; PrInv: primary invasive; Bord: borderline; Meta: metastatic; CI: confidence interval. 95%
CIs are computed using the bias-corrected bootstrap method using 1000 bootstrap samples.
* R1U variable selection: variable selection within the framework of least squares support vector machines that is based on rank 1 updates of the kernel
matrix [27].
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Page 8 of 12malignant tumors (cf. the c-index for benign versus
other tumors in Tables 3 and 4), this model performed
similar to the dichotomous models developed and vali-
dated on the same data [18,20]. LR-PC2 used 11 predic-
tors, but not subjective variables such as the experience
of abdominal or pelvic pain during the ultrasound
examination or the color score of intratumoral blood
flow (a subjective score between 1 and 4). These vari-
ables are used in some of the existing dichotomous
models [18,20]. None of the polytomous models used
the CA-125 tumor marker, because this marker was
deliberately not considered as a predictor. The most
Figure 1 Box plots of predicted probabilities given by model LR-PC2. Panel A displays results for the internal validation data, panel B
displays results for the aggregated temporal and external validation data. Be: Benign; Pr: Primary invasive; Bo: Borderline; Me: Metastatic.
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Page 9 of 12important reasons are that we focused on ultrasound
information, and that its use would preclude the
immediate use of a model as the results of the blood
test have to be awaited. In addition, the inclusion of
CA-125 as a variable in dichotomous models did not
result in better performance [34].
A disadvantage of combining 1-versus-1 models is that
the number of 1-versus-1 problems grows exponentially
with the total number of events. Another decomposition
of a polytomous problem that consists of a tree of
nested (or sequential) dichotomous models does not
suffer from this limitation [35,36]. A sensible tree in our
study would be to make a model to discriminate
between benign and malignant tumors, followed by a
model to discriminate between borderline and invasive
tumors, and finally a model to contrast primary with
metastatic invasive tumors. Polytomous probabilities can
be obtained in a straightforward manner. When we
applied this approach, it resulted in stronger perfor-
mance degeneration on temporal and external validation
than the true polytomous models or the pairwise cou-
pling approach.
Interestingly, we found that approaches based on
logistic regression performed very well when compared
to the regularized kernel-based alternatives despite the
fact that two events (borderline, metastatic) had very
few cases. All models suffered from performance
decrease on temporal and external validation, but the
decrease was not more severe for the unregularized
logistic regression-based models. This might be
explained by the careful variable selection strategies for
which cross-validated c-index estimates were the most
important criterion. If we applied pairwise coupling of
1-versus-1 logistic regression models based on standard
Figure 2 Calibration graphs for the internal, temporal, and external validation of LR-PC2.
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selection and removal threshold, we ended up with a
total of 15 selected variables. The polytomous and pair-
wise c-indexes of stepLR-PC were similar to or worse
than those of LR-PC2 and showed stronger decrease on
temporal and external validation. That being said, the
use of logistic regression models in situations like the
one in this study asks for a regularized fitting approach
such as shrinkage, penalized maximum likelihood esti-
mation, or the LASSO (least absolute selection and
shrinkage operator) [37].
This study further demonstrated the necessity of a
thorough validation of prediction models, in particular in
situations with small sample sizes for some events rela-
tive to the number of variables considered as possible
predictors. We observed in our study that, opposite to
what the internal validation results suggested, the differ-
entiation between primary and metastatic invasive
tumors was near random on temporal and external vali-
dation. Unfortunately, many models are developed yet
only a limited portion of these undergo validation in var-
ious clinical settings. This hampers the successful imple-
mentation of such models into clinical practice [38].
Even though the use of LR-PC2 in clinical practice
would provide useful information, future work will focus
on the development of a more robust model by combin-
ing all the data used in this study to update LR-PC2.
Ample attention will be devoted to the selection of a
limited set of predictors to boost the user-friendliness of
the model for busy clinicians.
Conclusions
This study shows that polytomous discrimination of
ovarian tumors can be obtained, while maintaining simi-
lar performance for the traditional dichotomous diagno-
sis (benign vs malignant) and without the need for more
predictors. Such models can provide highly useful infor-
mation for clinicians when having to make sensible treat-
ment decisions. For polytomous prediction, the
combination of dichotomous 1-versus-1 models is an
interesting alternative to true polytomous (all-at-once)
models. Despite two events (borderline, metastatic) with
relatively few cases, standard logistic regression
approaches performed similar to or better than regular-
ized kernel-based alternatives, a finding to which the
careful variable selection based on cross-validated c-
index estimates will have contributed. The importance of
model validation studies is clearly demonstrated as the
lack of discrimination between primary invasive and
metastatic invasive tumors became clear only on tem-
poral and external validation. Without thorough evalua-
tion of diagnostic performance, it is unsafe to implement
prediction models in clinical practice for decision
support.
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